Penn Study: Costly Eye Drug No Safer Than Alternative

 

Brian VanderBeek of the Perelman School of Medicine is highlighted for leading a study on the safety of a costly eye drug in comparison to its cheaper alternative.

・ From Philadelphia Inquirer